Nitric oxide (SB 204) - Novan

Drug Profile

Nitric oxide (SB 204) - Novan

Alternative Names: SB-204

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novan Inc
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Discontinued Staphylococcal infections

Most Recent Events

  • 07 Nov 2017 Novan plans a phase III trial for Acne vulgaris in 2018 before the planned NDA submission
  • 25 Sep 2017 Novan plans a pivotal trial for Acne vulgaris in USA
  • 07 Jul 2017 Pharmacodynamics data from an ex-vivo study released by Novan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top